Zimmer Biomet Stock Price Targets Adjusted Downward by Analysts

Several Wall Street analysts have lowered their price targets for Zimmer Biomet. JPMorgan set a $95 target, down from $100, while Goldman Sachs reduced its target to $86 from $89. Wells Fargo, Barclays, and Citizens have also made adjustments, lowering expectations for the company's share price.

Analysts have weighed in on Zimmer Biomet this week, with four major investment banks revising their price forecasts for the stock. Barclays adjusted its target to $94 from $100, while Goldman Sachs reduced its estimate to $86 from $89. JPMorgan set a $95 price target, a $5 cut from its prior estimate of $100. Meanwhile, Wells Fargo adjusted its target to $90 from $98, and Citizens also made a downward revision.

The coordinated reduction in price targets reflects analyst caution around ZBH's near-term earnings visibility, including ongoing concerns about procedure volume recovery in orthopedics and the competitive pressure the company faces from Smith & Nephew and Stryker in key joint reconstruction markets. Despite the downgrades, several banks maintained their buy or outperform ratings, suggesting analysts view the lower price targets as recalibration rather than a fundamental deterioration.

Zimmer Biomet has faced a challenging period navigating post-pandemic orthopedic procedure normalization, tariff-driven input cost headwinds, and integration complexity from its portfolio restructuring. Investors will be watching whether the company's upcoming earnings results can stabilize analyst sentiment or whether additional target cuts signal deeper concerns about competitive positioning in the large-joint reconstruction market.

Zimmer Biomet Stock Price Targets Adjusted Downward by Analysts

Related Stocks